Copa Holdings (CPA) closed the last trading session at $100.68, gaining 19% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $150.45 indicates a 49.4% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $20.25. While the lowest estimate of $120 indicates a 19.2% increase from the current price level, the most optimistic analyst expec ...

Roku (ROKU) closed the last trading session at $61.36, gaining 3.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $88.87 indicates a 44.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $17.78. While the lowest estimate of $60 indicates a 2.2% decline from the current price level, the most optimistic analyst expects the stock ...

Group 1 - The stock of Pros Holdings (PRO) closed at $16.87, reflecting a 2.1% gain over the past four weeks, with a mean price target of $28.86 indicating a potential upside of 71.1% [1] - The average price targets from analysts range from a low of $22 to a high of $38, with a standard deviation of $5.98, suggesting a variability in estimates; the lowest estimate indicates a 30.4% increase, while the highest suggests a 125.3% upside [2] - Analysts show a consensus that PRO will report better earnings than previously estimated, which is a positive indicator for potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 18.9% over the last 30 days, with three estimates moving higher and no negative revisions [12] - PRO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [13]

Group 1 - The stock of Priority Technology (PRTH) closed at $6.71, with a 2.1% gain over the past four weeks, and analysts set a mean price target of $12.80, indicating a potential upside of 90.8% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $2.77, where the lowest estimate is $10 (49% increase) and the highest is $16 (138.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.9% over the past month, indicating positive sentiment among analysts [12] - PRTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it suggests a positive direction for price movement [13]

Group 1: Financial Performance - InspireMD, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -29.41% [1] - The company posted revenues of $1.53 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.21%, and showing a slight increase from year-ago revenues of $1.51 million [2] - Over the last four quarters, InspireMD has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - InspireMD shares have declined approximately 1.1% since the beginning of the year, while the S&P 500 has seen a decline of -3.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $1.93 million, and for the current fiscal year, it is -$0.79 on revenues of $8.22 million [7] - The estimate revisions trend for InspireMD is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which InspireMD belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Adeia (ADEA) shares have increased by 4.4% over the past four weeks, closing at $13.10, with a mean price target of $17.33 indicating a potential upside of 32.3% [1] - The average price targets range from a low of $17 to a high of $18, with a standard deviation of $0.58, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about ADEA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for ADEA's current year earnings has increased by 1% over the past month, with no negative revisions [12] - ADEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Core Viewpoint - Novo Nordisk (NVO) shows potential for significant upside, with a mean price target of $102.16 indicating a 51.2% upside from the current price of $67.55 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from $61 to $160, with a standard deviation of $36.83, indicating variability among analysts [2] - The lowest estimate suggests a decline of 9.7%, while the highest points to a 136.9% upside [2] - Analysts' price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Market Sentiment - Analysts are optimistic about NVO's earnings prospects, with a trend of upward revisions in EPS estimates, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.4%, with three estimates moving higher and no negative revisions [12] - NVO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [13]

Group 1 - Si-Bone (SIBN) shares have increased by 25.5% over the past four weeks, closing at $17.47, with a mean price target of $24.67 indicating a potential upside of 41.2% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $3.57, where the lowest estimate is $19 (an 8.8% increase) and the highest is $32 (an 83.2% increase) [2] - Analysts show strong agreement on SIBN's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for SIBN has increased by 7% due to four upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - SIBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While price targets can be misleading, the direction implied by them may serve as a useful guide for further research into SIBN's fundamentals [10][11]

Shares of Immunome, Inc. (IMNM) have gained 19.7% over the past four weeks to close the last trading session at $7.43, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26 indicates a potential upside of 249.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.26. While the lowest estimate of $20 indicates a 169.2% increase from the curren ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...